Maze Therapeutics, Inc.

MAZE · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$30,087-$33,679-$32,786-$29,579
Dep. & Amort.$571$649$684$705
Deferred Tax$0$0$0$0
Stock-Based Comp.$3,864$3,237$3,226$2,851
Change in WC$2,463-$1,038-$1,425$1,031
Other Non-Cash-$1,453$779$785$2,540
Operating Cash Flow-$24,642-$30,052-$29,516-$22,452
Investing Activities
PP&E Inv.-$68-$393-$299-$605
Net Acquisitions$0$0$0$0
Inv. Purchases-$66,815$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$66,883-$393-$299-$605
Financing Activities
Debt Repay.$0$0$0-$16,176
Stock Issued-$128,364$612$127,752$70,262
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$272,121$0-$374$16,176
Financing Cash Flow$143,757$612$127,378$70,262
Forex Effect$0$0$0$0
Net Chg. in Cash$52,232-$29,833$97,563$47,205
Supplemental Information
Beg. Cash$265,630$295,463$197,900$150,695
End Cash$317,862$265,630$295,463$197,900
Free Cash Flow-$24,710-$30,445-$29,815-$23,057
Maze Therapeutics, Inc. (MAZE) Financial Statements & Key Stats | AlphaPilot